Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. Oppenheimer & Co. Inc. and Citizens JMP are acting as joint book-running managers for the offering. Stephens Inc. is acting as lead manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio’s INO-3107 shows efficacy in Phase 1/2 RRP trial
- Inovio price target lowered to $15 from $33 at Oppenheimer
- Inovio price target lowered to $5 from $12 at H.C. Wainwright
- Inovio Pharmaceuticals Advances DNA Medicine Development
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance